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The management of mucosal leishmaniasis in immu-
nocompromised patients is not standardized and lim-
ited data are available on the use of miltefosine for 
treatment and secondary prophylaxis. We describe a 
case of mucosal leishmaniasis in an HIV-coinfected pa-
SUMMARY
tient treated with miltefosine due to a severe allergic 
reaction to liposomal amphotericin B.
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n INTRODUCTION
In people infected with HIV, the clinical mani-festations of leishmaniasis may be heterogene-
ous and not strictly species-specific [1]. The par-
asites can lose their typical tropism and mucosal 
involvement (mucosal leishmaniasis, ML) is not 
a rare event in the Old World, particularly in the 
immunocompromised patients [1]. Treatment 
of this co-infection is not standardized and may 
be complicated by a high risk of recurrence [2]. 
The use of liposomal amphotericin B (L-AmB) is 
sometimes associated to adverse events, making 
alternative therapy necessary [2]. Data on the use 
of miltefosine for treatment and secondary proph-
ylaxis in patients with ML and HIV-coinfection 
are extremely limited [2-4].
Here we describe a case of ML in a patient with 
HIV infection, treated with miltefosine after a se-
vere allergic reaction to L-AmB.
n CASE REPORT
A 59-year-old male Nigerian patient with mucosal 
leishmaniasis was referred to our hospital in June 
2018. He reported uncontrolled arterial hyperten-
sion, recent thoracic herpes zoster and no other 
known major comorbidity. He had lived in Italy 
for more than 40 years and returned periodically 
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to Nigeria (the last time had been two years earli-
er). Due to a months-long history of nasal obstruc-
tion, he underwent ENT (ear, nose and throat) as-
sessment that revealed hyperplastic hemorrhagic 
vestibular mucosa with external swelling of the 
left nostril. The subsequent biopsy showed gran-
ulomatosis compatible with leishmaniasis (Figure 
1, A and B), confirmed by the positivity to SSUrD-
NA nested-PCR [5]. The parasite was identified as 
belonging to the Leishmania donovani complex by 
ITS1-PCR-RFLP analysis performed at the Italian 
National Institute of Health (U.O. Vector-borne 
diseases, Rome, Italy) [6]. On admission the pa-
tient was in good clinical condition and physi-
cal examination only revealed an exudative and 
stenosing lesion in the left nasal vestibule with-
out fibrolaringoscopic evidence of pharyngeal or 
glottic lesions. Laboratory tests showed a white 
blood cells count (WBC) of 4,410 cells/mm3 (1,330 
neutrophils), alanine aminotransferase (ALT) 80 
IU/mL, and monoclonal hypergammaglobuline-
mia (31%). Serology was positive for HIV and 
HIV-1 RNA was 252,000 copies/mL (subtype G); 
the CD4 count was 140 cells/mm3. No major drug 
resistance mutation was detected. Leishmania real 
time PCR on peripheral whole blood (Stat Nat 
Leishmania spp, Sentinel Diagnostic, Italy) and 
serology (IFAT, Euroimmun, Lübeck, Germany) 
were negative. No other co-infections were detect-
ed. Chest X-ray was normal; liver steatosis was 
detected by abdominal ultrasound. Left ventricu-
lar hypertrophy was documented by echocardi-
ography. Magnetic resonance of the brain showed 
leukoaraiosis. The patient started antiretroviral 
therapy (ART) (tenofovir alafenamide/emtricit-
abine + dolutegravir) responding with a rapid de-
crease in HIV-1 RNA; cotrimoxazole was given for 
prophylaxis of opportunistic infections. To treat 
ML, L-AmB was administered with a scheduled 
dose of 4mg/Kg/day on days 1-5, 10, 17, 24, 31 
and 38, associated with steroid treatment (intra-
venous methylprednisolone at dosage of 20 mg/
day). On day 10, during the administration of the 
sixth dose of L-Amb (and 48 hours after starting 
the antiviral drugs), the patient developed ana-
phylactic shock with severe oedema of the glottis 
requiring intubation and admission to the inten-
sive care unit. In the following days, tracheosto-
my was performed due to persistent inflamma-
tion of the glottis and the difficulty in extubation. 
PCR for Leishmania was negative in the arytenoid 
mucosa. Two weeks later, the tracheostomy tube 
was removed, and the patient was transferred to 
the Infectious Disease Unit. Oral miltefosine (50 
mg x 3/day) was introduced and well tolerated. 
The patient was discharged on day 49 with a mac-
Figure 1 - (A) Granulomatous 
inflammation is observed with-
in chorion in Hematoxylin/
Eosin (magnification 400x); (B) 
Numerous Leishmania amas-
tigotes highlighted by Giemsa 
stain (magnification 1000x).
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roscopic regression of the nasal lesion. After com-
pleting 4 weeks of therapy, miltefosine was ad-
ministered as secondary prophylaxis at a dosage 
of 50 mg x 2/day. At subsequent follow-up there 
were no signs of recurrence or macroscopic nasal 
mucosa lesions; after 10 months HIV-1 RNA was 
no longer detectable, CD4 count was 215 cells/
mm3, and there was no significant alteration of 
liver or kidney function. The patient is continuing 
miltefosine until sustained immunological recov-
ery and tolerates it well. 
n DISCUSSION
Leishmaniasis was a relatively frequent oppor-
tunistic disease during the HIV-related epidem-
ic, especially in the Mediterranean area; for this 
reason the visceral form (visceral leishmaniasis, 
VL) was included as a stage 4, AIDS-defining con-
dition in the World Health Organization (WHO) 
clinical staging system for HIV [1,2,7]. Although 
our patient probably contracted the parasite in-
fection in Italy, where L. infantum is the only 
known endemic species, genotyping suggests 
that it is not possible to exclude reactivation of a 
prior latent infection due to immunosuppression 
[2]. In fact, very few autochthonous cases of VL 
are reported in Nigeria [8]. L. infantum is usual-
ly associated with VL, however atypical features 
including cutaneous and mucosal involvement, 
isolated or in combination with VL, have been de-
scribed in immunocompromised patients [9,10]. 
In severely immunocompromised HIV-positive 
subjects (CD4 <50 mm3), atypical amastigotes 
localizations (digestive tract, lung, skin, tonsils) 
have been reported in up to 41% of HIV-positive 
subjects with VL in Southern France [11].
In our case, isolated ML was also the first unmask-
ing HIV condition in a late-presenter patient [12].
In most cases, histological examination combined 
with molecular techniques can confirm suspected 
ML, whereas treatment and long-term suppres-
sion are more complex, especially for the high 
risk of recurrence [2, 13]. There is no first-choice 
treatment for ML, and therapy must be person-
alized [2]. Uncontrolled data from case report se-
ries have been published regarding therapy with 
L-AmB (not FDA-approved for ML) [2, 14]. Lim-
ited data from two non-randomized-controlled 
trials conducted in the region of Bolivia, where 
L. braziliensis is endemic, shows a 71% cure rate, 
for ML patients treated with miltefosine [15,16]. 
Miltefosine is therefore only FDA-approved for 
ML caused only by L. braziliensis and is consid-
ered less effective for leishmaniasis caused by L. 
infantum-chagasi, the etiological agent of our case 
[2]. A recent study seems to confirm the natural re-
sistance of Leishmania infantum to miltefosine con-
tributing to the treatment failure of visceral leish-
maniasis in Brazil [17]. Even less data is available 
for ML in immunocompromised patients, an un-
explored context in which systemic therapy, like 
for VL, is suggested [2]. The FDA-approved total 
dose of L-AmB for VL in immunocompromised 
hosts is 40 mg/kg but there is little evidence to 
suggest that miltefosine is effective [2]. An inter-
esting recent randomized trial showed that the 
sequential use of L-AmB (30 mg/kg) followed 
by miltefosine (100 mg/28 days) is more effective 
in patients with VL and HIV in Ethiopia [18]. A 
similar result was previously documented in In-
dia with a combined treatment [3]. These findings 
could modify or direct the current recommenda-
tions if confirmed in other areas and with other 
Leishmania species. In line with available evidence 
we treated the patient with L-AmB but soon had 
to suspend it due to life-threatening anaphylaxis, 
despite prophylactic administration of steroids, 
expected in the treatment of ML [2]. L-AmB is not 
only a high-cost drug but can also have serious 
side effects. Acute infusion reaction and comple-
ment-activation-related-pseudoallergy (CARPA) 
have been described and could bring to select 
an alternative treatment as in our case [2]. It is 
difficult to determine whether the simultaneous 
administration of antiretroviral therapy and the 
risk of a Jarisch-Herxheimer reaction during ML 
treatment have contributed to the adverse event 
[2]. The subsequent tolerability of antiretroviral 
therapy and the negativity of Leishmania DNA in 
the laryngeal specimen seem to confirm the hy-
pothesis of an anaphylactoid reaction to L-AMB. 
In co-infected HIV patients with VL, post-treat-
ment relapses are much more common and sec-
ondary prophylaxis is therefore recommended, 
usually with L-AmB, while experience using 
miltefosine in this setting is limited [2, 19]. Dis-
continuation can be considered in patients whose 
CD4 cell count on antiretroviral therapy has been 
>200-350 cells/mm3 for at least 6 months [2]. In 
HIV-infected patients with cutaneous or mucosal 
leishmaniasis, secondary prophylaxis is not rou-
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tinely recommended under current guidelines 
but is only suggested for immunocompromised 
patients with cutaneous leishmaniasis who have 
multiple relapses after adequate treatment [2, 19]. 
However, in our case, considering the life-threat-
ening course of the disease, the adverse reaction 
to L-AmB, and the patient’s very good tolerance 
of the miltefosine, this drug was used for second-
ary prophylaxis. At 10-month follow up there 
were no signs of parasitic relapse or toxicity and 
the treatment is still ongoing until sustained im-
munological recovery is achieved.
In conclusion, the present case confirms that man-
agement of ML with HIV-coinfection is complex, 
and the treatment with miltefosine alone or in 
combination with L-AmB may be a valid thera-
peutic alternative. 
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